US President Joe Biden declared the pandemic ‘over’ in a “60 Minutes” interview this Sunday, September 18th. In response, many vaccine manufacturers saw a drop in share prices, including Moderna, Novavax, and BioNTech. This reflects a larger dip in the biotech market, particularly companies working with COVID-19 therapeutics.
According to Fierce Pharma, “After reporting a profit of £19.2 million in last year’s first half, Oxford Biomedica has swung to a loss of £27.4 million in the first half of 2022, The Business Magazine reports. The company has been a key manufacturing partner for AstraZeneca, but the pharma giant’s shot is seeing lower demand these days.”
To read more, click here.
(Source: Fierce Pharma, September 19th, 2022)
